Yazar "Kiraz, Sedat" için PubMed İndeksli Yayın Koleksiyonu listeleme
-
Biological and targeted-synthetic disease-modifying antirheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: Real-life TReasure prospective data
Kimyon, G.; Kalyoncu, Umut; Kiraz, Sedat; Bes, Cemal; Coşkun, Necdet; Yagiz, B.; Kelesoglu, B.; Mercan, Rıdvan (Clinical and Experimental Rheumatology S.A.S., 2021)Objective To determine the real-life efficacy, safety, and drug-retention rates of leflunomide (LEF) or methotrexate (MTX) as a synthetic DMARD used in combination with biological DMARDs for rheumatoid arthritis (RA). ... -
The First Effect of COVID-19 Pandemic on Starting Biological Disease Modifying Anti-Rheumatic Drugs: Outcomes from the TReasure Real-Life Database
Kanıtez, Nilüfer Alpay; Kiraz, Sedat; Dalkılıç, Ediz; Kimyon, Gezmiş; Mercan, Rıdvan; Karadağ, Ömer; Beş, Cemal; Mercan, Rıdvan (Aves, 2022)Objective: The coronavirus disease 2019 pandemic has been resulting in increased hospital occupancy rates. Rheumatic patients cannot still reach to hospitals, or they hesitate about going to a hospital even they are able ... -
In the era of disease-modifying antirheumatic drugs, how close are we to treating rheumatoid arthritis without the use of glucocorticoids?
Yağız, Burcu; Coşkun, Belkıs Nihan; Pehlivan, Yavuz; Dalkılıç, Ediz; Kiraz, Sedat; Yazısız, Veli; Kalyoncu, Umut; Mercan, Rıdvan (Springer Heidelberg, 2021)We wanted to see how close we could get to our goal of treating rheumatoid arthritis (RA) without the use of glucocorticoids (GCs) in the disease-modifying antirheumatic drugs (DMARDs) era using real-life data. Established ... -
Methodology of a new inflammatory arthritis registry: TReasure
Kalyoncu, Umut; Tascilar, Etem Koray; Ertenli, Ali İhsan; Dalkılıç, Hüseyin Ediz; Bes, Cemal; Küçükşahin, Orhan; Kiraz, Sedat; Mercan, Rıdvan (Tubitak Scientific & Technical Research Council Turkey, 2018)Background/aim: The TReasure registry, created in 2017, is an observational multicenter cohort that includes inflammatory arthritis patients. This article reviews the methodology and objectives of the TReasure registry ... -
Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic
Kalyoncu, Umut; Pehlivan, Yavuz; Akar, Servet; Kaşifoğlu, Timuçin; Kimyon, G.; Karadağ, Ö.; Kiraz, Sedat; Mercan, Rıdvan (Turkiye Klinikleri, 2021)Background/aim: To evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis receiving bDMARDs within the first 100 days after the announcement of the COVID-19 pandemic. ...